已知或疑似子宫内膜异位症对其他适应证行FDG PET/CT报告解读的干扰
该研究分析了18例已知(15例)或疑似(3例)子宫内膜异位症患者的18F-FDG PET/CT图像,这些检查均因其他适应证而进行。经临床随访及其他影像、活检和/或术后组织学确认,18例中13例(72%)存在子宫内膜异位症病灶;基于患者的PET/CT阳性率为8/18(44%;95%CI 22%-69%),在确认病灶患者中的检出率为8/13(62%;CI 32%-86%),基于病灶/部位为11/20(55%)。作者结论认为干扰有限但可能存在,需予以注意,即使在绝经后女性中也是如此。
要点
- 18例已知或疑似子宫内膜异位症患者因其他适应证行18F-FDG PET/CT,13例(72%)经确认存在子宫内膜异位症病灶。
- 基于患者的PET/CT阳性率为8/18(44%;95%CI 22%-69%),确认病灶患者中检出率为8/13(62%;CI 32%-86%)。
- 子宫内膜异位症病灶SUVmax为1.8-5.3(中位3.8),与低度恶性肿瘤存在重叠,最高值5.3略高于既往提出的恶性转化阈值4。
核心结论
- 已知或疑似子宫内膜异位症对其他适应证行18F-FDG PET/CT报告解读的干扰有限但可能存在,应予以注意,即使在绝经后女性中也是如此,因为FDG阳性的子宫内膜异位症患者中最年长者为63岁。
- 子宫内膜异位症病灶的18F-FDG摄取不一致,其SUVmax与低度恶性肿瘤存在重叠。
- 本系列中子宫内膜异位症病灶的最高SUVmax值为5.3,略高于既往提出的用于识别子宫内膜异位症恶性转化的阈值4。
研究设计与样本
- 对18例已知(n=15)或疑似(n=3)子宫内膜异位症女性的18F-FDG PET/CT图像进行分析,这些检查均因其他适应证而进行。
- 通过临床随访及其他影像、活检和/或术后组织学结果确认检查时子宫内膜异位症病灶的存在。
主要发现
- 18例患者中13例(72%)经临床随访及其他影像、活检和/或术后组织学确认存在子宫内膜异位症病灶。
- 18F-FDG PET/CT基于患者的阳性率为8/18(44%;95%CI 22%-69%)。
- 在确认子宫内膜异位症病灶的患者中,18F-FDG PET/CT基于患者的检出率为8/13(62%;CI 32%-86%)。
- 基于病灶/部位,18F-FDG PET/CT检出20个子宫内膜异位症部位中的11个(55%)。
- 这些病灶/部位的SUVmax范围为1.8-5.3(中位3.8);18例中9例(50%)共检出13个非子宫内膜异位症相关病灶/部位,其SUVmax范围为2.7-23(中位9.4)。
临床怎么用
- 作者结论认为,已知或疑似子宫内膜异位症对其他适应证行18F-FDG PET/CT报告解读的干扰有限但可能存在,应予以注意,即使在绝经后女性中也是如此。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Endometriosis is a common gynecologic condition that may be visualized on 18F-FDG PET/CT and mimic lesions of malignancy. We analyzed the interference of known or suspected endometriosis in reporting 18F-FDG PET/CT performed in another indication. RESULTS: The PET/CT images of 18 women with known (n = 15) or suspected (n = 3) endometriosis were analyzed. Based on clinical follow-up and results of other imaging, biopsy, and/or postsurgical histology, the presence of lesions of endometriosis at the time of 18F-FDG PET/CT was confirmed in 13 of 18 patients (72%). The per-patient positivity rate of 18F-FDG PET/CT was 8/18 (44%; 95% confidence interval, 22%-69%). The patient-based detection rate of 18F-FDG PET/CT in patients with confirmed lesions of endometriosis was 8/13 (62%; confidence interval, 32%-86%). On per-lesion/site basis, 18F-FDG PET/CT detected 11 of 20 sites (55%) of endometriosis. The SUVmax of these lesions/sites ranged between 1.8 and 5.3 (median, 3.8). In 9 of 18 patients (50%), a total of 13 non-endometriosis-related lesions/sites were detected by 18F-FDG PET/CT; their SUVmax ranged between 2.7 and 23 (median, 9.4). CONCLUSION: The interference of known or suspected endometriosis in reporting 18F-FDG PET/CT performed in another indication was limited but possible and should be kept in mind, even in postmenopausal women, as the oldest patient with 18F-FDG-positive endometriosis was aged 63 years. The lesions of endometriosis showed inconstant 18F-FDG uptake with overlap of SUVmax with low-grade malignancies. In our series, the greatest SUVmax value of lesion of endometriosis was 5.3, somewhat higher than the threshold of 4 previously proposed for identification of malignant transformation of endometriosis.
引用
- Balogova S, Daraï E, Noskovicova L, et al. Interference of Known or Suspected Endometriosis in Reporting FDG PET/CT Performed in Another Indication. Clin Nucl Med. 2022. PMID: 35119396. doi:10.1097/RLU.0000000000004049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。